恩杂鲁胺对转移性激素敏感性前列腺癌影像学进展而无PSA进展的影响:ENZAMET试验回顾分析
ENZAMET试验随机分配1125例转移性激素敏感性前列腺癌患者接受恩杂鲁胺或标准非甾体抗雄激素联合雄激素剥夺治疗。分析显示,影像学进展而无PSA进展(不一致进展,DP)发生率为10%,占所有进展事件的30%;恩杂鲁胺延迟DP(HR 0.66)和其他进展(HR 0.37),并改善总生存(HR 0.70)。DP组5年OS率低于其他进展组。
要点
- 恩杂鲁胺延长总生存(HR 0.70,95%CI 0.58-0.84;p<0.0001)。
- DP发生率为10%(114/1125),占进展事件的30%。
- 恩杂鲁胺延迟DP(HR 0.66,95%CI 0.46-0.96;p=0.03)。
核心结论
- 恩杂鲁胺延长转移性激素敏感性前列腺癌患者的总生存,并延迟影像学进展而无PSA进展(DP)和其他进展。
- DP与更差的总生存相关,且不受治疗影响。
研究设计与样本
- ENZAMET试验的事后探索性分析,纳入1125例转移性激素敏感性前列腺癌患者。
- 使用多状态Cox比例风险回归模型分析疾病状态转换。
主要发现
- 恩杂鲁胺组与NSAA组的DP比例相似(48% vs 52%)。
- 恩杂鲁胺延迟DP(HR 0.66,95%CI 0.46-0.96;p=0.03)和OP(HR 0.37,95%CI 0.31-0.44;p<0.001)。
- DP组5年OS率为24%,低于OP组的42%。
- 无进展的495例参与者中,51例(10%)死于非前列腺癌原因(中位随访68个月)。
临床怎么用
- 在转移性激素敏感性前列腺癌中,定期影像学检查可能优于针对症状的影像学检查。
- 恩杂鲁胺可延迟DP和OP,并改善总生存。
局限性
- 本分析为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: ENZAMET randomised 1125 participants with metastatic hormone-sensitive prostate cancer to receive enzalutamide or a standard nonsteroidal antiandrogen (NSAA) combined with testosterone suppression with or without docetaxel. Enzalutamide demonstrated superior progression-free and overall survival (OS). Radiographic progression without prior/concurrent prostate-specific antigen progression (discordant progression; DP) portends poor outcomes. Our aim was to determine the frequency of DP in ENZAMET and the impact of enzalutamide on disease-state transitions. METHODS: A multistate Cox proportional-hazards regression model was used to partition participants into four states: (1) event-free; (2) discordant progression (DP); (3) other types of progression (other progression; OP); and (4) death. KEY FINDINGS AND LIMITATIONS: Enzalutamide prolonged OS in the entire cohort of 1125 participants (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.58-0.84; p < 0.0001). Radiographic progression occurred in 388/1125 (34%) participants, and DP in 114/1125 (10%), with similar proportions in the enzalutamide arm (55/114, 48%) and NSAA arm (59/114, 52%). Participant characteristics in the DP group were similar between the treatment arms. Enzalutamide delayed DP (HR 0.66, 95% CI 0.46-0.96; p = 0.03) and OP (HR 0.37, 95% CI 0.31-0.44; p < 0.001). The 5-yr OS rate was lower in the DP group (24%) than in the OP group (42%). Among participants whose cancer had not progressed (495/1125), 51/495 (10%) died of non-prostate cancer causes (median follow-up 68 mo). This exploratory analysis is limited by its post hoc nature. CONCLUSIONS AND CLINICAL IMPLICATIONS: DP occurred in 10% of participants and accounted for 30% of progression events observed in ENZAMET. DP was associated with worse OS regardless of treatment. Enzalutamide delayed DP and reduced the risk of DP and OP. Regularly scheduled imaging may be preferable to for-cause imaging in metastatic hormone-sensitive prostate cancer.
引用
- Inderjeeth AJ, Martin AJ, Zielinski RR, et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. 2026. PMID: 41633909. doi:10.1016/j.euo.2026.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。